Lancman and colleagues find that infection risk in patients treated with anti-BCMA bispecific antibodies for relapsed/refractory multiple myeloma is associated with severe immunoglobulin deficiency and may be mitigated by immunoglobulin replacement therapy. The study has implications for managing infection risk and raises questions about the optimal duration of treatment with these potent, novel immunotherapies.
Understanding Infection Risk with Anti-BCMA Bispecific Antibodies
Blood Cancer Discov 2023;4:427–9
Alfred L. Garfall, Edward A. Stadtmauer; Understanding Infection Risk with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov 1 November 2023; 4 (6): 427–429. https://doi.org/10.1158/2643-3230.BCD-23-0157
Download citation file:
Citing articles via